Proteon Therapeutics Stock Price, News & Analysis (NASDAQ:PRTO)

$2.30 0.00 (0.00 %)
(As of 02/22/2018 04:00 PM ET)
Previous Close$2.30
Today's Range$2.30 - $2.50
52-Week Range$1.10 - $2.85
Volume62,081 shs
Average Volume74,930 shs
Market Capitalization$37.88 million
P/E RatioN/A
Dividend YieldN/A
Beta1.78

About Proteon Therapeutics (NASDAQ:PRTO)

Proteon Therapeutics logoProteon Therapeutics, Inc. is a late-stage biopharmaceutical company, which focuses on the development of pharmaceuticals to address the needs of patients with renal and vascular disease. The Company is involved in research and development activities. The Company's product candidate, product candidate, vonapanitase, formerly PRT-201, is a recombinant human elastase that it is developing to manage vascular access failure in patients with chronic kidney disease undergoing or planning for hemodialysis, a lifesaving treatment that cannot be conducted without a functioning vascular access. The Company has completed Phase II trial of vonapanitase in patients undergoing creation of an arteriovenous fistula (AVF). The Company initiated the first of two Phase III trials, PATENCY-1, for vonapanitase in radiocephalic AVFs. Its vonapanitase product candidate is a recombinant human elastase under development as a treatment to prevent AVF and arteriovenous graft (AVG) patency loss.

Receive PRTO News and Ratings via Email

Sign-up to receive the latest news and ratings for PRTO and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Bio Therapeutic Drugs
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:PRTO
CUSIPN/A
Phone781-890-0102

Debt

Debt-to-Equity RatioN/A
Current Ratio5.28%
Quick Ratio5.28%

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book Value$2.32 per share
Price / Book0.99

Profitability

Trailing EPS($2.22)
Net Income$-28,520,000.00
Net MarginsN/A
Return on Equity-105.58%
Return on Assets-77.60%

Miscellaneous

Employees19
Outstanding Shares17,620,000

Proteon Therapeutics (NASDAQ:PRTO) Frequently Asked Questions

What is Proteon Therapeutics' stock symbol?

Proteon Therapeutics trades on the NASDAQ under the ticker symbol "PRTO."

How were Proteon Therapeutics' earnings last quarter?

Proteon Therapeutics Inc (NASDAQ:PRTO) posted its earnings results on Monday, August, 7th. The biopharmaceutical company reported ($0.33) earnings per share for the quarter, beating analysts' consensus estimates of ($0.44) by $0.11. View Proteon Therapeutics' Earnings History.

When will Proteon Therapeutics make its next earnings announcement?

Proteon Therapeutics is scheduled to release their next quarterly earnings announcement on Wednesday, March, 14th 2018. View Earnings Estimates for Proteon Therapeutics.

Where is Proteon Therapeutics' stock going? Where will Proteon Therapeutics' stock price be in 2018?

5 analysts have issued 12-month target prices for Proteon Therapeutics' stock. Their predictions range from $2.00 to $6.00. On average, they expect Proteon Therapeutics' stock price to reach $3.43 in the next twelve months. View Analyst Ratings for Proteon Therapeutics.

What are Wall Street analysts saying about Proteon Therapeutics stock?

Here are some recent quotes from research analysts about Proteon Therapeutics stock:

  • 1. According to Zacks Investment Research, "Proteon Therapeutics Inc. is a biopharmaceutical company. The Company is developing pharmaceuticals to address the medical needs of patients with kidney and vascular diseases. It is developing PRT-201, a recombinant human elastase, applied in a single treatment to the external surface of arteries and veins during an open surgical procedure or an endovascular intervention. Proteon Therapeutics Inc. is headquartered in Waltham, Mass. " (1/11/2018)
  • 2. Robert W. Baird analysts commented, "Focus of the call was on changes to the ongoing PATENCY-2 study of vonapanitase, following disappointing results from the first identically designed PATENCY-1 study announced late last year. Key changes, supported by the FDA, include a reordering of the primary endpoint (now a co-primary) and expanding the study (300 to 500 patients), with data now expected in 4Q18 (2Q18 previously). While we are encouraged by a potential path forward for vonapanitase, lack of meaningful updates near-term keeps us on the sidelines." (3/16/2017)
  • 3. Maxim Group analysts commented, "Proteon reported YE16 with a net loss of $28.5M and ended the year with $41M in cash on the balance sheet." (3/16/2017)

Who are some of Proteon Therapeutics' key competitors?

Who are Proteon Therapeutics' key executives?

Proteon Therapeutics' management team includes the folowing people:

  • Paul J. Hastings, Chairman of the Board (Age 57)
  • Timothy P. Noyes, President, CEO, Director (Age 55)
  • George A. Eldridge, Chief Financial Officer, Senior Vice President, Treasurer, Assistant Secretary, IR Contact Officer (Age 54)
  • E. Scott Toner, Senior Vice President - Marketing (Age 62)
  • Steven K. Burke M.D., Senior Vice President, Chief Medical Officer (Age 56)
  • Matthew Paul Kowalsky, Vice President, Legal and Secretary (Age 44)
  • Daniel P. Gottlieb, Vice President - Corporate Development (Age 46)
  • Jonathan Leff, Director
  • Hubert Birner Ph.D., Independent Director (Age 51)
  • Garen G. Bohlin, Independent Director (Age 69)

Who owns Proteon Therapeutics stock?

Proteon Therapeutics' stock is owned by a number of of institutional and retail investors. Top institutional shareholders include Renaissance Technologies LLC (1.14%). Company insiders that own Proteon Therapeutics stock include George Arthur Eldridge, James E Flynn and Steven Keith Burke. View Institutional Ownership Trends for Proteon Therapeutics.

Who bought Proteon Therapeutics stock? Who is buying Proteon Therapeutics stock?

Proteon Therapeutics' stock was acquired by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC. Company insiders that have bought Proteon Therapeutics stock in the last two years include George Arthur Eldridge, James E Flynn and Steven Keith Burke. View Insider Buying and Selling for Proteon Therapeutics.

How do I buy Proteon Therapeutics stock?

Shares of Proteon Therapeutics can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Proteon Therapeutics' stock price today?

One share of Proteon Therapeutics stock can currently be purchased for approximately $2.30.

How big of a company is Proteon Therapeutics?

Proteon Therapeutics has a market capitalization of $37.88 million. The biopharmaceutical company earns $-28,520,000.00 in net income (profit) each year or ($2.22) on an earnings per share basis. Proteon Therapeutics employs 19 workers across the globe.

How can I contact Proteon Therapeutics?

Proteon Therapeutics' mailing address is 200 WEST STREET, WALTHAM MA, 02451. The biopharmaceutical company can be reached via phone at 781-890-0102 or via email at [email protected]


MarketBeat Community Rating for Proteon Therapeutics (PRTO)

Community Ranking:  2.5 out of 5 (star star half star)
Outperform Votes:  113 (Vote Outperform)
Underperform Votes:  114 (Vote Underperform)
Total Votes:  227
MarketBeat's community ratings are surveys of what our community members think about Proteon Therapeutics and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Proteon Therapeutics (NASDAQ:PRTO) Analysts' Consensus Rating

  (How are Consensus Ratings Calculated?)
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: HoldHoldHoldHold
Consensus Rating Score: 2.202.202.132.13
Ratings Breakdown: 0 Sell Rating(s)
4 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
4 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
7 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
7 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $3.43$3.43$6.86$9.00
Price Target Upside: 85.59% upside85.59% upside270.81% upside592.31% upside

Proteon Therapeutics (NASDAQ:PRTO) Consensus Price Target History

Price Target History for Proteon Therapeutics (NASDAQ:PRTO)

Proteon Therapeutics (NASDAQ:PRTO) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
11/10/2017Robert W. BairdReiterated RatingHold$2.00N/AView Rating Details
11/8/2017HC WainwrightReiterated RatingHold$2.30N/AView Rating Details
8/16/2017OppenheimerReiterated RatingMarket PerformLowView Rating Details
8/8/2017CowenReiterated RatingHoldLowView Rating Details
5/4/2017Maxim GroupSet Price TargetBuy$6.00HighView Rating Details
12/14/2016Raymond James FinancialReiterated RatingStrong-Buy -> Market PerformN/AView Rating Details
12/14/2016JMP SecuritiesDowngradeOutperform -> Market PerformN/AView Rating Details
12/14/2016Stifel NicolausDowngradeBuy -> Hold$19.00 -> $3.00N/AView Rating Details
(Data available from 2/22/2016 forward)

Earnings

Proteon Therapeutics (NASDAQ:PRTO) Earnings History and Estimates Chart

Earnings by Quarter for Proteon Therapeutics (NASDAQ:PRTO)

Proteon Therapeutics (NASDAQ PRTO) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
3/14/2018($0.45)N/AView Earnings Details
11/7/2017Q3 2017($0.40)($1.08)ViewN/AView Earnings Details
8/7/2017Q2 2017($0.44)($0.33)ViewN/AView Earnings Details
5/10/2017Q1 2017($0.43)($0.39)ViewN/AView Earnings Details
3/16/2017Q4 2016($0.43)($0.42)ViewN/AView Earnings Details
11/7/2016Q3 2016($0.46)($0.43)ViewN/AView Earnings Details
8/8/2016Q2 2016($0.42)($0.48)ViewN/AView Earnings Details
5/9/2016Q1($0.41)($0.40)ViewN/AView Earnings Details
3/14/2016($0.34)($0.39)ViewN/AView Earnings Details
11/12/2015Q315($0.33)($0.33)ViewN/AView Earnings Details
8/13/2015Q215($0.30)($0.31)ViewN/AView Earnings Details
5/13/2015($0.24)($0.28)ViewN/AView Earnings Details
3/20/2015($0.26)($0.24)ViewN/AView Earnings Details
11/25/2014($0.31)($31.03)$2.95 millionViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Estimates

Proteon Therapeutics (NASDAQ:PRTO) Earnings Estimates

Current Year EPS Consensus Estimate: $-1.88 EPS
Next Year EPS Consensus Estimate: $-1.71 EPS

Dividends

Dividend History for Proteon Therapeutics (NASDAQ:PRTO)


No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Proteon Therapeutics (NASDAQ PRTO) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 36.30%
Institutional Ownership Percentage: 49.99%
Insider Trades by Quarter for Proteon Therapeutics (NASDAQ:PRTO)
Institutional Ownership by Quarter for Proteon Therapeutics (NASDAQ:PRTO)

Proteon Therapeutics (NASDAQ PRTO) Insider Trades by Quarter

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
12/15/2017Steven Keith BurkeSVPBuy12,000$1.88$22,560.00117,535View SEC Filing  
11/30/2017James E FlynnDirectorBuy110,557$1.75$193,474.75View SEC Filing  
11/14/2017George Arthur EldridgeCFOBuy295$1.69$498.55View SEC Filing  
6/6/2016George Arthur EldridgeCFOBuy4,000$5.78$23,120.002,750View SEC Filing  
12/1/2015Timothy P. NoyesCEOSell5,000$14.97$74,850.00View SEC Filing  
11/2/2015Timothy P. NoyesCEOSell5,000$13.50$67,500.00View SEC Filing  
10/1/2015Timothy P. NoyesCEOSell5,000$13.33$66,650.00View SEC Filing  
9/8/2015Timothy P. NoyesCEOSell5,000$13.55$67,750.00View SEC Filing  
7/7/2015Daniel Philip GottliebVPSell1,965$16.86$33,129.90View SEC Filing  
10/27/2014James E FlynnInsiderBuy691,713$10.00$6,917,130.00View SEC Filing  
10/27/2014Skyline Venture Partners QualiMajor ShareholderSell56,038$10.00$560,380.00View SEC Filing  
10/27/2014Timothy HainesDirectorBuy950,000$10.00$9,500,000.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Proteon Therapeutics (NASDAQ PRTO) News Headlines

Source:
DateHeadline
Analyzing Proteon Therapeutics (PRTO) & Sorrento Therapeutics (SRNE)Analyzing Proteon Therapeutics (PRTO) & Sorrento Therapeutics (SRNE)
www.americanbankingnews.com - February 6 at 1:14 AM
Proteon Therapeutics Inc (PRTO) Given Consensus Recommendation of "Hold" by BrokeragesProteon Therapeutics Inc (PRTO) Given Consensus Recommendation of "Hold" by Brokerages
www.americanbankingnews.com - February 2 at 7:42 PM
 Analysts Anticipate Proteon Therapeutics Inc (PRTO) Will Announce Earnings of -$0.43 Per Share Analysts Anticipate Proteon Therapeutics Inc (PRTO) Will Announce Earnings of -$0.43 Per Share
www.americanbankingnews.com - February 2 at 1:16 AM
Proteon Therapeutics Inc (PRTO) Given Average Recommendation of "Hold" by BrokeragesProteon Therapeutics Inc (PRTO) Given Average Recommendation of "Hold" by Brokerages
www.americanbankingnews.com - January 8 at 5:34 PM
Proteon Therapeutics (PRTO) Lifted to Hold at Zacks Investment ResearchProteon Therapeutics (PRTO) Lifted to Hold at Zacks Investment Research
www.americanbankingnews.com - January 7 at 11:52 PM
Zacks: Analysts Anticipate Proteon Therapeutics Inc (PRTO) Will Post Earnings of -$0.43 Per ShareZacks: Analysts Anticipate Proteon Therapeutics Inc (PRTO) Will Post Earnings of -$0.43 Per Share
www.americanbankingnews.com - December 30 at 7:46 AM
Reviewing Aduro BioTech (ADRO) and Proteon Therapeutics (PRTO)Reviewing Aduro BioTech (ADRO) and Proteon Therapeutics (PRTO)
www.americanbankingnews.com - December 25 at 11:42 PM
Proteon Therapeutics Inc (PRTO) SVP Steven Keith Burke Purchases 12,000 SharesProteon Therapeutics Inc (PRTO) SVP Steven Keith Burke Purchases 12,000 Shares
www.americanbankingnews.com - December 18 at 6:52 PM
Proteon Therapeutics Inc (PRTO) Given Consensus Rating of "Hold" by BrokeragesProteon Therapeutics Inc (PRTO) Given Consensus Rating of "Hold" by Brokerages
www.americanbankingnews.com - December 14 at 9:28 PM
Reviewing Proteon Therapeutics (PRTO) and The CompetitionReviewing Proteon Therapeutics (PRTO) and The Competition
www.americanbankingnews.com - December 14 at 1:28 PM
-$0.43 EPS Expected for Proteon Therapeutics Inc (PRTO) This Quarter-$0.43 EPS Expected for Proteon Therapeutics Inc (PRTO) This Quarter
www.americanbankingnews.com - December 13 at 3:24 AM
Proteon Therapeutics (PRTO) & Its Peers Financial ContrastProteon Therapeutics (PRTO) & Its Peers Financial Contrast
www.americanbankingnews.com - December 9 at 3:14 AM
Proteon Therapeutics (PRTO) and Its Peers Head-To-Head ReviewProteon Therapeutics (PRTO) and Its Peers Head-To-Head Review
www.americanbankingnews.com - December 9 at 3:14 AM
Proteon Therapeutics Inc (PRTO) Director Acquires $193,474.75 in StockProteon Therapeutics Inc (PRTO) Director Acquires $193,474.75 in Stock
www.americanbankingnews.com - December 4 at 6:36 PM
Critical Contrast: Proteon Therapeutics (PRTO) versus Its PeersCritical Contrast: Proteon Therapeutics (PRTO) versus Its Peers
www.americanbankingnews.com - December 4 at 1:30 PM
-$0.41 Earnings Per Share Expected for Proteon Therapeutics, Inc. (PRTO) This Quarter-$0.41 Earnings Per Share Expected for Proteon Therapeutics, Inc. (PRTO) This Quarter
www.americanbankingnews.com - November 25 at 9:26 AM
Proteon Therapeutics, Inc. (PRTO) Given Average Recommendation of "Hold" by AnalystsProteon Therapeutics, Inc. (PRTO) Given Average Recommendation of "Hold" by Analysts
www.americanbankingnews.com - November 19 at 5:34 PM
Analyzing Proteon Therapeutics (PRTO) & The CompetitionAnalyzing Proteon Therapeutics (PRTO) & The Competition
www.americanbankingnews.com - November 16 at 3:36 PM
Proteon Therapeutics, Inc. (PRTO) Earns "Hold" Rating from Robert W. BairdProteon Therapeutics, Inc. (PRTO) Earns "Hold" Rating from Robert W. Baird
www.americanbankingnews.com - November 11 at 11:12 AM
Proteon Therapeutics, Inc. (PRTO) Rating Lowered to Strong Sell at Zacks Investment ResearchProteon Therapeutics, Inc. (PRTO) Rating Lowered to Strong Sell at Zacks Investment Research
www.americanbankingnews.com - November 11 at 7:16 AM
Proteon Therapeutics to Present at the Stifel 2017 Healthcare Conference November 15thProteon Therapeutics to Present at the Stifel 2017 Healthcare Conference November 15th
finance.yahoo.com - November 9 at 11:56 AM
Proteon Therapeutics Announces Third Quarter 2017 Financial ResultsProteon Therapeutics Announces Third Quarter 2017 Financial Results
finance.yahoo.com - November 7 at 9:03 AM
Proteon Therapeutics reports 3Q lossProteon Therapeutics reports 3Q loss
finance.yahoo.com - November 7 at 9:03 AM
-$0.40 EPS Expected for Proteon Therapeutics, Inc. (PRTO) This Quarter-$0.40 EPS Expected for Proteon Therapeutics, Inc. (PRTO) This Quarter
www.americanbankingnews.com - November 6 at 9:59 AM
Critical Comparison: Biopharmx Corp (BPMX) vs. Proteon Therapeutics (PRTO)Critical Comparison: Biopharmx Corp (BPMX) vs. Proteon Therapeutics (PRTO)
www.americanbankingnews.com - November 4 at 9:28 PM
Critical Review: Intec Pharma (NTEC) vs. Proteon Therapeutics (PRTO)Critical Review: Intec Pharma (NTEC) vs. Proteon Therapeutics (PRTO)
www.americanbankingnews.com - November 1 at 2:20 PM
Proteon Therapeutics, Inc. (PRTO) Set to Announce Quarterly Earnings on MondayProteon Therapeutics, Inc. (PRTO) Set to Announce Quarterly Earnings on Monday
www.americanbankingnews.com - October 30 at 9:54 AM
Proteon Therapeutics, Inc. (PRTO) Given Average Recommendation of "Hold" by BrokeragesProteon Therapeutics, Inc. (PRTO) Given Average Recommendation of "Hold" by Brokerages
www.americanbankingnews.com - October 25 at 9:52 PM
Zacks Investment Research Downgrades Proteon Therapeutics, Inc. (PRTO) to HoldZacks Investment Research Downgrades Proteon Therapeutics, Inc. (PRTO) to Hold
www.americanbankingnews.com - October 18 at 6:08 AM
Zacks: Brokerages Anticipate Proteon Therapeutics, Inc. (PRTO) to Post -$0.40 EPSZacks: Brokerages Anticipate Proteon Therapeutics, Inc. (PRTO) to Post -$0.40 EPS
www.americanbankingnews.com - October 17 at 6:22 PM
Proteon Therapeutics, Inc. (PRTO) Given Consensus Rating of "Hold" by BrokeragesProteon Therapeutics, Inc. (PRTO) Given Consensus Rating of "Hold" by Brokerages
www.americanbankingnews.com - September 30 at 8:34 PM
Head-To-Head Contrast: NeuroDerm (NDRM) & Proteon Therapeutics (PRTO)Head-To-Head Contrast: NeuroDerm (NDRM) & Proteon Therapeutics (PRTO)
www.americanbankingnews.com - September 22 at 6:06 AM
Proteon Therapeutics to Present at the Baird 2017 Global Healthcare Conference September 7, 2017Proteon Therapeutics to Present at the Baird 2017 Global Healthcare Conference September 7, 2017
finance.yahoo.com - September 6 at 7:28 AM
Proteon Therapeutics, Inc. (PRTO) Receives Consensus Rating of "Hold" from BrokeragesProteon Therapeutics, Inc. (PRTO) Receives Consensus Rating of "Hold" from Brokerages
www.americanbankingnews.com - September 5 at 9:00 PM
-$0.39 Earnings Per Share Expected for Proteon Therapeutics, Inc. (PRTO) This Quarter-$0.39 Earnings Per Share Expected for Proteon Therapeutics, Inc. (PRTO) This Quarter
www.americanbankingnews.com - August 22 at 4:14 PM
Proteon Therapeutics, Inc. (PRTO) Forecasted to Earn Q3 2017 Earnings of ($0.34) Per ShareProteon Therapeutics, Inc. (PRTO) Forecasted to Earn Q3 2017 Earnings of ($0.34) Per Share
www.americanbankingnews.com - August 18 at 6:26 AM
Proteon Therapeutics (PRTO) "Market Perform" Rating Reiterated at Oppenheimer Holdings, Inc.Proteon Therapeutics' (PRTO) "Market Perform" Rating Reiterated at Oppenheimer Holdings, Inc.
www.americanbankingnews.com - August 16 at 2:41 PM
Proteon Therapeutics, Inc. (PRTO) Receives Average Recommendation of "Hold" from BrokeragesProteon Therapeutics, Inc. (PRTO) Receives Average Recommendation of "Hold" from Brokerages
www.americanbankingnews.com - August 11 at 9:06 PM
Proteon Therapeutics (NASDAQ:PRTO) "Hold" Rating Reiterated at Cowen and CompanyProteon Therapeutics' (NASDAQ:PRTO) "Hold" Rating Reiterated at Cowen and Company
www.americanbankingnews.com - August 9 at 12:38 AM
Proteon Therapeutics, Inc. (NASDAQ:PRTO) Posts Quarterly  Earnings Results, Beats Estimates By $0.11 EPSProteon Therapeutics, Inc. (NASDAQ:PRTO) Posts Quarterly Earnings Results, Beats Estimates By $0.11 EPS
www.americanbankingnews.com - August 8 at 11:14 AM
Proteon Therapeutics Announces Second Quarter 2017 Financial ResultsProteon Therapeutics Announces Second Quarter 2017 Financial Results
finance.yahoo.com - August 8 at 6:22 AM
Proteon Therapeutics, Inc. (NASDAQ:PRTO) Expected to Post Earnings of -$0.45 Per ShareProteon Therapeutics, Inc. (NASDAQ:PRTO) Expected to Post Earnings of -$0.45 Per Share
www.americanbankingnews.com - August 4 at 12:28 PM
Proteon Therapeutics Announces Closing of $22 Million Convertible Preferred Stock FinancingProteon Therapeutics Announces Closing of $22 Million Convertible Preferred Stock Financing
finance.yahoo.com - August 3 at 7:06 AM
Proteon Therapeutics, Inc. (NASDAQ:PRTO) Receives Consensus Recommendation of "Hold" from AnalystsProteon Therapeutics, Inc. (NASDAQ:PRTO) Receives Consensus Recommendation of "Hold" from Analysts
www.americanbankingnews.com - July 17 at 8:28 PM
Proteon Therapeutics, Inc. (PRTO) Expected to Post Earnings of -$0.45 Per ShareProteon Therapeutics, Inc. (PRTO) Expected to Post Earnings of -$0.45 Per Share
www.americanbankingnews.com - July 13 at 8:29 AM
Proteon Therapeutics Announces First Quarter 2017 Financial ResultsProteon Therapeutics Announces First Quarter 2017 Financial Results
globenewswire.com - May 10 at 7:33 PM
Pre-Open Stock Movers 05/10: (PRTO) (NVDA) (INCR) Higher; (YELP) (VSI) (FOSL) Lower (more...)Pre-Open Stock Movers 05/10: (PRTO) (NVDA) (INCR) Higher; (YELP) (VSI) (FOSL) Lower (more...)
www.streetinsider.com - May 10 at 11:29 AM
Proteon Therapeutics Receives FDA Breakthrough Therapy Designation for VonapanitaseProteon Therapeutics Receives FDA Breakthrough Therapy Designation for Vonapanitase
www.nasdaq.com - May 10 at 11:29 AM
Proteon Therapeutics reports 1Q lossProteon Therapeutics reports 1Q loss
marketbeat.com - May 10 at 8:13 AM
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces the Commencement of an Investigation Involving Possible ... - Business Wire (press release)SHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces the Commencement of an Investigation Involving Possible ... - Business Wire (press release)
www.businesswire.com - March 24 at 8:16 AM

SEC Filings

Proteon Therapeutics (NASDAQ:PRTO) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Proteon Therapeutics (NASDAQ:PRTO) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Proteon Therapeutics (NASDAQ PRTO) Stock Chart for Thursday, February, 22, 2018

Loading chart…

This page was last updated on 2/22/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.